The Consumer Bankers Association Executive Banking School is scheduled to start July 27 at Furman University in Greenville.

CBA’s Executive Banking School has been held in Greenville since 2015, bringing banking leaders to town each year for a developmental program.

More than 4,500 bankers have graduated from the school over the past seven decades, some of them going on to become executives at the nation’s largest banks. The 10-day course features classes taught by industry veterans and informational sessions on pressing issues facing the banking industry.

Attendees will include Lindsey Johnson, President and CEO of the Consumer Bankers Association, Michelle Lee, Regional Banking Executive, Branch Banking at Wells Fargo and Quincy Miller, President of Eastern Bank.

Among this year’s speakers will be Atlantic Union Bank CEO John Asbury, who will speak about leading a mid-sized regional bank through an increasingly competitive banking landscape; and Cassandra McKinney, head of Retail Bank at Comerica, will discuss the ongoing war for talent.

The school will take place July 27-Aug 2.

Ingevity (NYSE: NGVT) announced the company recently awarded 30 high school seniors, including five from South Carolina, with $2,000 college scholarships.

This was Ingevity’s fifth year awarding scholarships to students demonstrating strong leadership and educational abilities along with a passion for community service.

Winners were selected from high schools in the following locations where the company operates: Covington, Virginia; Crossett, Arkansas; DeRidder, Louisiana; North Charleston, South Carolina; Waynesboro, Georgia; and Wickliffe, Kentucky.

The South Carolina scholarship recipients are listed below by name, high school attended, college or university they plan to attend and intended major:

• Lenaysa Brown, Fort Dorchester High School, Howard University, Psychology
• Jada Fickling, Charleston School of the Arts, Claflin University, Elementary Education
• Ja’Nayia Sincere Gourdine, Center for Advanced Studies and North Charleston High School, Clemson University, Engineering
• Brooklyn Murphy, Hanahan High School, Clemson University, Biology
• Kissara Yvonne Elayne Stewart, Center for Advanced Studies and Stall High School, Clemson University, Engineering.

 The Active & Fit Direct program has added Camp Gladiator to its Premium Fitness Center Network, which provides program members with access to 5,000-plus top fitness studios, outdoor fitness programs, and boot camps nationally at a 20 to 70 percent discount on most centers, studios, and programs.

The Premium Fitness Studio Network is offered in addition to the Active&Fit Direct Standard Fitness Center Membership program where members can select from 11,000-plus local gyms and brand-name fitness center chains for $25 per month plus an enrollment fee and applicable taxes.

With Camp Gladiator, Active&Fit Direct members have unlimited access to work out at any of the 7,500+ weekly outdoor classes in 11 states: Arizona, Arkansas, Colorado, Florida, Georgia, Louisiana, North Carolina, Oklahoma, South Carolina, Tennessee, and Texas.

Members who don't have access to a local workout or prefer to work out at home can stream any of Camp Gladiator's 1,500+ weekly LIVE online classes via a laptop, tablet, TV, or smartphone.

Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, announced the enrollment of the first participant in a Phase 1 clinical trial of their intranasal BLB-201 vaccine for RSV (respiratory syncytial virus) in Charleston, South Carolina. 

In preclinical studies, BLB-201, delivered intranasally as a single dose, induces serum antibody and mucosal antibody responses as well as cell-mediated immune responses, and is protective against RSV challenge infection in various animal models.

Delivered through the nose without injections, Blue Lake's intranasal vaccines have the potential to facilitate delivery of vaccines to broad populations, including pediatric and needle-hesitant individuals.

"The enrollment of the first participant in this RSV vaccine study is an important milestone for Blue Lake," said Dr. Biao He, founder and CEO. "We now have two clinical stage programs – a COVID-19 vaccine and an RSV vaccine using our intranasal PIV5-vectored vaccine platform, which we expect will confirm the broad utility of our platform."

The study is a multi-center, open-label trial being conducted in Charleston as well as Cincinnati, Ohio.

It will evaluate the safety, reactogenicity and immunogenicity of a single dose of BLB-201 administered intranasally to adults in the age groups of 18-59 and 60-75. 

Safety data will be collected and analyzed, as will antibody and cellular immune responses to the RSV F protein. 

RSV is a highly contagious respiratory virus that infects more than 64 million people worldwide each year.